Hemispherx Biopharma, Inc

Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherxs flagship products include Alferon N Injection and the experimental therapeutics Ampligen. Ampligen is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system, including Chronic Fatigue Syndrome. Hemispherxs platform technology includes components for potential treatment of various severely debilitating and life threatening diseases. Because Ampligen is experimental in nature, they are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials. The FDA approval of Alferon N Injection is limited to the treatment of refractory or recurrent external genital warts in patients 18 years of age or older. The Companys Alferon N approval in Argentina inc...